. "9-beta-D-Arabinofuranosyl-9H-purin-6-amine"@en . . "Vidarabine stops replication of herpes viral DNA in 2 ways: 1) competitive inhibition of viral DNA polymerase, and consequently 2) incorporation into and termination of the growing viral DNA chain. This drug is a nucleoside analog and therefore has to be phosphorylated to be active. Vidarabine is sequentially phosphorylated by kinases to the triphosphate ara-ATP. This is the active form of vidarabine and is both an inhibitor and a substrate of viral DNA polymerase. When used as a substrate for viral DNA polymerase, ara-ATP competitively inhibits dATP leading to the formation of \u2018faulty\u2019 DNA. This is where ara-ATP is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand"@en . "9-beta-D-Arabinofuranosyladenine"@en . . "2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol"@en . . . . . . . . "approved"@en . . "Spongoadenosine"@en . . . . . "Human Herpes Virus"@en . . . . . . "9-\u03B2-D-arabinofuranosyladenine"@en . "9-beta-D-arabinofuranosyl-adenine"@en . . . . . . . . . . . . . . . "A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the vaccinia VIRUS and varicella zoster virus. [PubChem]"@en . . "24356-66-9"@en . " "@en . . . "Vidarabine"@en . "Acute massive overdosage by oral ingestion of the ophthalmic ointment has not occurred. However, the rapid deamination to arabinosylhypoxanthine should preclude any difficulty. The oral LD₅₀ for vidarabine is greater than 5020 mg/kg in mice and rats. No untoward effects should result from ingestion of the entire contents of the tube. Overdosage by ocular instillation is unlikely because any excess should be quickly expelled from the conjunctival sac."@en . "Systemetic absorption of vidarabine should not be expected to occur following ocular administration and swallowing lacrimal secretions. "@en . "24-38%"@en . . . . "Vidarabine"@en . . "9-\u03B2-D-arabinofuranosyl-9H-purin-6-amine"@en . "For treatment of chickenpox - varicella, herpes zoster and herpes simplex"@en . . . . . . . . . . .